Gilteritinib · Xospata, ASP-2215

What is Gilteritinib?

Gilteritinib is an orally bioavailable small-molecule inhibitor of receptor tyrosine kinases, primarily FLT3, and also AXL, ALK, and LTK. It binds to and inhibits both wild-type and mutated forms of these kinases, blocking their signal transduction and reducing proliferation in cancer cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Xospata, ASP-2215

Drug type

Small molecule

Targets

FMS-like tyrosine kinase 3 (FLT3), AXL (secondary target), anaplastic lymphoma kinase (ALK) (secondary target), leukocyte receptor tyrosine kinase (LTK) (secondary target)

Mechanism

Inhibitor of FMS-like tyrosine kinase 3 (FLT3)

Pathways

FLT3-mediated signal transduction, AXL-mediated signal transduction, ALK-mediated signal transduction, LTK-mediated signal transduction

Therapy area

Hematology, Oncology

Developer

Astellas

In trials of

SNDX

FDA status

Approved as Xospata (November 28, 2018), NDA211349 · FDA label

UNII

66D92MGC8M

✅ FDA-approved uses

• Relapsed or Refractory Acute Myeloid Leukemia with FLT3 mutation

From the indications section of the FDA label (version of Jan 1, 2022). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on FLT3

Sources

• FDA label (DailyMed)
• FDA label Xospata (2022-01-01), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT03013998
• ClinicalTrials.gov NCT03013998

Updated Oct 3, 2026.